Review of delirium in patients with Parkinson’s disease

Journal of Neurology

Volumn 262, Issue 11, 2015, Pages 2401-2410

  Vardy, Emma R L C ^a,b   Teodorczuk, Andrew ^c,d   Yarnall, Alison J ^a,b  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d TYNE AND WEAR NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cognition; Delirium; Parkinson s disease; Pathology; Prevalence; Treatment

Indexed keywords

ACETYLCHOLINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE; HALOPERIDOL; NEUROTRANSMITTER; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ATTENTION; AWARENESS; DELIRIUM; DISEASE ASSOCIATION; EMBASE; GENETIC ASSOCIATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFLAMMATION; MEDLINE; MORBIDITY; MORTALITY; MOTOR SYSTEM; PARKINSON DISEASE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; COMORBIDITY; COMPLICATION;

COMORBIDITY; DELIRIUM; HUMANS; PARKINSON DISEASE;

EID: 84956846993     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-015-7760-1     Document Type: Review

References (72)

1. Pringsheim T, Jette N, Frolkis A, Steeves TD (2014) The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 29(13):1583–1590
2. Chaudhuri KR, Martinez-Martin P, Schapira AH et al (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 21(7):916–923
3. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (DSM-V), 5th edn. American Psychiatric Association, Washington DC
4. Akunne A, Murthy L, Young J (2012) Cost-effectiveness of multi-component interventions to prevent delirium in older people admitted to medical wards. Age Ageing 41(3):285–291
5. Maclullich AM, Ferguson KJ, Miller T, de Rooij SE, Cunningham C (2008) Unravelling the pathophysiology of delirium: a focus on the role of aberrant stress responses. J Psychosom Res 65(3):229–238
6. Lubomski M, Rushworth RL, Tisch S (2015) Hospitalisation and comorbidities in Parkinson’s disease: a large Australian retrospective study. J Neurol Neurosurg Psychiatry 86(3):324–330
7. Gerlach OH, Broen MP, Weber WE (2013) Motor outcomes during hospitalization in Parkinson’s disease patients: a prospective study. Parkinsonism Relat Disord 19(8):737–741
8. Golden WE, Lavender RC, Metzer WS (1989) Acute postoperative confusion and hallucinations in Parkinson’s disease. Ann Intern Med 111(3):218–222
9. Boorsma M, Joling KJ, Frijters DH, Ribbe ME, Nijpels G, van Hout HP (2012) The prevalence, incidence and risk factors for delirium in Dutch nursing homes and residential care homes. Int J Geriatr Psychiatry 27(7):709–715
10. Ahmed S, Leurent B, Sampson EL (2014) Risk factors for incident delirium among older people in acute hospital medical units: a systematic review and meta-analysis. Age Ageing 43(3):326–333
11. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60(3):387–392
12. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23(6):837–844
13. Davis DH, Skelly DT, Murray C et al (2015) Worsening cognitive impairment and neurodegenerative pathology progressively increase risk for delirium. Am J Geriatr Psychiatry 23(4):403–415
14. Klein C, Prokhorov T, Miniovitz A, Dobronevsky E, Rabey JM (2009) Admission of Parkinsonian patients to a neurological ward in a community hospital. J Neural Transm 116(11):1509–1512
15. Holroyd S, Currie L, Wooten GF (2001) Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry 70(6):734–738
16. Buchanan RJ, Wang S, Huang C, Simpson P, Manyam BV (2002) Analyses of nursing home residents with Parkinson’s disease using the minimum data set. Parkinsonism Relat Disord 8(5):369–380
17. Carlson JD, Neumiller JJ, Swain LD, Mark J, McLeod P, Hirschauer J (2014) Postoperative delirium in Parkinson’s disease patients following deep brain stimulation surgery. J Clin Neurosci 21(7):1192–1195
18. Woodford H, Walker R (2005) Emergency hospital admissions in idiopathic Parkinson’s disease. Mov Disord 20(9):1104–1108
19. Glover A, Bradshaw LE, Watson N et al (2014) Diagnoses, problems and healthcare interventions amongst older people with an unscheduled hospital admission who have concurrent mental health problems: a prevalence study. BMC Geriatr 14:43
20. Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD (2004) Parkinsonism in Ontario: comorbidity associated with hospitalization in a large cohort. Mov Disord 19(1):49–53
21. Martignoni E, Godi L, Citterio A et al (2004) Comorbid disorders and hospitalisation in Parkinson’s disease: a prospective study. Neurol Sci 25(2):66–71
22. Temlett JA, Thompson PD (2006) Reasons for admission to hospital for Parkinson’s disease. Intern Med J 36(8):524–526
23. Serrano-Duenas M, Bleda MJ (2005) Delirium in Parkinson’s disease patients. a five-year follow-up study. Parkinsonism Relat Disord 11(6):387–392
24. Umemura A, Oeda T, Tomita S et al (2014) Delirium and high fever are associated with subacute motor deterioration in Parkinson disease: a nested case–control study. PLoS One 9(6):e94944
25. Vida S, Galbaud du Fort G, Kakuma R, Arsenault L, Platt RW, Wolfson CM (2006) An 18-month prospective cohort study of functional outcome of delirium in elderly patients: activities of daily living. Int Psychogeriatr 18(4):681–700
26. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI (1990) Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med 113(12):941–948
27. Inouye SK, Westendorp RG, Saczynski JS (2014) Delirium in elderly people. Lancet 383(9920):911–922
28. Yarnall AJ, Rochester L, Burn DJ (2011) The interplay of cholinergic function, attention, and falls in Parkinson’s disease. Mov Disord 26(14):2496–2503
29. Bellelli G, Speciale S, Morghen S, Torpilliesi T, Turco R, Trabucchi M (2011) Are fluctuations in motor performance a diagnostic sign of delirium? J Am Med Dir Assoc 12(8):578–583
30. Tiraboschi P, Hansen LA, Alford M et al (2000) Cholinergic dysfunction in diseases with Lewy bodies. Neurology 54(2):407–411
31. Bohnen NI, Kaufer DI, Ivanco LS et al (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60(12):1745–1748
32. Shimada H, Hirano S, Shinotoh H et al (2009) Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73(4):273–278
33. Bohnen NI, Albin RL (2011) The cholinergic system and Parkinson disease. Behav Brain Res 221(2):564–573
34. Hshieh TT, Fong TG, Marcantonio ER, Inouye SK (2008) Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence. J Gerontol Seri A Biol Sci Med Sci 63(7):764–772
35. Flacker JM, Cummings V, Mach JR Jr, Bettin K, Kiely DK, Wei J (1998) The association of serum anticholinergic activity with delirium in elderly medical patients. Am J Geriatr Psychiatry 6(1):31–41
36. van Munster BC, de Rooij SE, Yazdanpanah M et al (2010) The association of the dopamine transporter gene and the dopamine receptor 2 gene with delirium, a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 153B(2):648–655
37. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211
38. Forno LS (1996) Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol 55(3):259–272
39. Cunningham C, Maclullich AM (2013) At the extreme end of the psychoneuroimmunological spectrum: delirium as a maladaptive sickness behaviour response. Brain Behav Immun 28:1–13
40. Godoy MCP, Tarelli R, Ferrari CC, Sarchi MIS, Pitossi FJ (2008) Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson’s disease. Brain 131:1880–1894
41. Godoy MCP, Ferrari CC, Pitossi FJ (2010) Nigral neurodegeneration triggered by striatal AdIL-1 administration can be exacerbated by systemic IL-1 expression. J Neuroimmunol 222(1–2):29–39
42. Munster BC, Aronica E, Zwinderman AH, Eikelenboom P, Cunningham C, Rooij SE (2011) Neuroinflammation in delirium: a postmortem case–control study. Rejuvenation Res 14(6):615–622
43. van Munster BC, Korevaar JC, Zwinderman AH, Levi M, Wiersinga WJ, De Rooij SE (2008) Time-course of cytokines during delirium in elderly patients with hip fractures. J Am Geriatr Soc 56(9):1704–1709
44. Field R, Campion S, Warren C, Murray C, Cunningham C (2010) Systemic challenge with the TLR3 agonist poly I: C induces amplified IFNα/β and IL-1β responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun 24:996–1007
45. Cunningham C (2011) Systemic inflammation and delirium: important co-factors in the progression of dementia. Biochem Soc Trans 39(4):945–953
46. Kouti L, Noroozian M, Akhondzadeh S et al (2013) Nitric oxide and peroxynitrite serum levels in Parkinson’s disease: correlation of oxidative stress and the severity of the disease. Eur Rev Med Pharmacol Sci 17(7):964–970
47. Field RH, Gossen A, Cunningham C (2012) Prior pathology in the basal forebrain cholinergic system predisposes to inflammation-induced working memory deficits: reconciling inflammatory and cholinergic hypotheses of delirium. J Neurosci 32(18):6288–6294
48. van Munster BC, Korevaar JC, Zwinderman AH, Leeflang MM, de Rooij SE (2009) The association between delirium and the apolipoprotein E epsilon 4 allele: new study results and a meta-analysis. Am J Geriatr Psychiatry 17(10):856–862
49. Ely EW, Girard TD, Shintani AK et al (2007) Apolipoprotein E4 polymorphism as a genetic predisposition to delirium in critically ill patients. Crit Care Med 35(1):112–117
50. Tagarakis GI, Tsolaki-Tagaraki F, Tsolaki M, Diegeler A, Tsilimingas NB, Papassotiropoulos A (2007) The role of apolipoprotein E in cognitive decline and delirium after bypass heart operations. Am J Alzheimers Dis Other Demen 22(3):223–228
51. Williams-Gray CH, Goris A, Saiki M et al (2009) Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s disease. J Neurol 256(3):493–498
52. Morley JF, Xie SX, Hurtig HI et al (2012) Genetic influences on cognitive decline in Parkinson’s disease. Mov Disord 27(4):512–518
53. Fong TG, Bogardus ST, Daftary A et al (2006) Cerebral perfusion changes in older delirious patients using 99mTc HMPAO SPECT. J Gerontol Ser A Biol Sci Med Sci 61(12):1294–1299
54. Morandi A, Rogers BP, Gunther ML et al (2012) The relationship between delirium duration, white matter integrity, and cognitive impairment in intensive care unit survivors as determined by diffusion tensor imaging: the VISIONS prospective cohort magnetic resonance imaging study. Crit Care Med 40(7):2182–2189
55. Figiel GS, Krishnan KR, Doraiswamy PM (1990) Subcortical structural changes in ECT-induced delirium. J Geriatr Psychiatry Neurol 3(3):172–176
56. Gore RL, Vardy ER, O’Brien JT (2015) Delirium and dementia with Lewy bodies: distinct diagnoses or part of the same spectrum? J Neurol Neurosurg Psychiatry 86(1):50–59
57. Sunwoo MK, Hong JY, Choi J, Park HJ, Kim SH, Lee PH (2013) alpha-Synuclein pathology is related to postoperative delirium in patients undergoing gastrectomy. Neurology 80(9):810–813
58. Lieberman A (1998) Managing the neuropsychiatric symptoms of Parkinson’s disease. Neurology 50(6 Suppl 6):S33–S38 discussion S44-8
59. Schrag A (2004) Psychiatric aspects of Parkinson’s disease—an update. J Neurol 251(7):795–804
60. Hindle JV (2013) The practical management of cognitive impairment and psychosis in the older Parkinson’s disease patient. J Neural Transm 120:649–653
61. Lonergan E, Britton AM, Luxenberg J, Wyller T (2007) Antipsychotics for delirium. Cochrane Database Syst Rev (2):CD005594
62. Boettger S, Jenewein J, Breitbart W (2014) Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: a comparison of efficacy, safety, and side effects. Palliat Support Care 5:1–7
63. Pae CU, Lee SJ, Lee CU, Lee C, Paik IH (2004) A pilot trial of quetiapine for the treatment of patients with delirium. Hum Psychopharmacol 19(2):125–127
64. Sasaki Y, Matsuyama T, Inoue S et al (2003) A prospective, open-label, flexible-dose study of quetiapine in the treatment of delirium. J Clin Psychiatry 64(11):1316–1321
65. Tahir TA, Eeles E, Karapareddy V et al (2010) A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. J Psychosom Res 69(5):485–490
66. Yoon HJ, Park KM, Choi WJ et al (2013) Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. BMC Psychiatry 13:240
67. Maneeton B, Maneeton N, Srisurapanont M, Chittawatanarat K (2013) Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial. Drug Des Devel Ther 7:657–667
68. Seppi K, Weintraub D, Coelho M et al (2011) The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):S42–S80
69. Lonergan E, Luxenberg J, Areosa Sastre A, Wyller TB (2009) Benzodiazepines for delirium. Cochrane Database Syst Rev (4):CD006379. doi:10.1002/14651858.CD006379.pub3
70. Davis DH, Muniz Terrera G, Keage H et al (2012) Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study. Brain 135(Pt 9):2809–2816
71. Witlox J, Eurelings LS, de Jonghe JF, Kalisvaart KJ, Eikelenboom P, van Gool WA (2010) Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. JAMA 304(4):443–451
72. Gross AL, Jones RN, Habtemariam DA et al (2012) Delirium and long-term cognitive trajectory among persons with dementia. Arch Intern Med 172(17):1324–1331